Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.49 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1722276 | 0.98 | SIGMAR1 (0.50) | SIGMAR1HTR2CHTR2AHTR2BIDO1 | |
| SCHEMBL9307221 | 0.86 | SIGMAR1 (0.50) | SIGMAR1HTR2CHTR2AHTR2B | |
| SCHEMBL10724594 | 0.86 | HTR2A (0.49) | SIGMAR1HTR2CHTR2AHTR2B | |
| SCHEMBL9307226 | 0.86 | SIGMAR1 (0.50) | SIGMAR1HTR2CHTR2AHTR2B | |
| SCHEMBL9307217 | 0.86 | SIGMAR1 (0.50) | SIGMAR1HTR2CHTR2AHTR2B | |
| SCHEMBL1897659 | 0.81 | HTR2C (0.59) | SIGMAR1HTR2CHTR2AHTR2B | |
| SCHEMBL9278829 | 0.81 | HTR2C (0.59) | SIGMAR1HTR2CHTR2AHTR2B | |
| SCHEMBL28748526 | 0.80 | PRCP (0.46) | SIGMAR1HTR2CHTR2AHTR2BSRD5A1 | |
| SCHEMBL852627 | 0.79 | MEN1 (0.53) | HTR2CHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL9672275 | 0.79 | HTR2C (0.57) | SIGMAR1HTR2CHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773773-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2009-07-29 | — | — | EP | claimed |
| EP-1773773-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-04-18 | — | — | EP | claimed |
| US-20060009491-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-01-12 | — | — | US | claimed |
| WO-2006002350-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-01-05 | — | — | WO | claimed |
| EP-0095666-B1 | TETRAHYDRO-BENZO(E) ISOINDOLINES | ABBOTT LABORATORIES (US) | 1989-01-18 | — | — | EP | claimed |
| US-8729274-B2 | Tricyclic heterocyclic derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-05-20 | — | — | US | disclosed |
| US-20120232122-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2012-09-13 | — | — | US | disclosed |
| EP-2406217-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | MSD Oss B.V. (NL) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010103001-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON (NL) | 2010-09-16 | — | — | WO | disclosed |
| EP-1773773-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-1773773-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-04-18 | — | — | EP | disclosed |
| US-7101892-B2 | Sulfone derivatives as 5-HT7 receptor ligands | MERCK SHARP & DOHME LTD. | 2006-09-05 | — | — | US | disclosed |
| EP-0891362-A1 | PYRROLOPYRROLONE DERIVATIVES AS INHIBITORS OF NEUTROPHIL ELASTASE | GLAXO GROUP LIMITED (GB) | 1999-01-20 | — | — | EP | disclosed |
| EP-0808318-A1 | TRICYCLIC SUBSTITUTED HEXAHYDROBENZ E]ISOINDOLE ALPHA-1 ADRENERGIC ANTAGONISTS | Abbott Laboratories (US) | 1997-11-26 | — | — | EP | disclosed |
| WO-1997036903-A1 | PYRROLOPYRROLONE DERIVATIVES AS INHIBITORS OF NEUTROPHIL ELASTASE | GLAXO GROUP LIMITED (GB) | 1997-10-09 | — | — | WO | disclosed |
| WO-1996022992-A1 | TRICYCLIC SUBSTITUTED HEXAHYDROBENZ[E]ISOINDOLE ALPHA-1 ADRENERGIC ANTAGONISTS | ABBOTT LABORATORIES (US) | 1996-08-01 | — | — | WO | disclosed |
| WO-1996022991-A1 | BICYCLIC SUBSTITUTED HEXAHYDROBENZ[E]ISOINDOLE ALPHA-1- ADRENERGIC ANTAGONISTS | ABBOTT LABORATORIES (US) | 1996-08-01 | — | — | WO | disclosed |
| WO-1993008166-A1 | BENZO-ISOQUINOLINE DERIVATIVES AND ANALOGS AND THEIR USE IN THERAPEUTICS | THE UPJOHN COMPANY (US) | 1993-04-29 | — | — | WO | disclosed |
| EP-0539209-A1 | Benzo-isoquinoline derivatives and analogs and their use in therapeutics | THE UPJOHN COMPANY (US) | 1993-04-28 | — | — | EP | disclosed |
| EP-0095666-B1 | TETRAHYDRO-BENZO(E) ISOINDOLINES | ABBOTT LABORATORIES (US) | 1989-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232122-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | TPH1, HTR3C, TPH2 | SIGMAR1 314/4885HTR2C 4/4885HTR2A 16/4885 |
| US-20060009491-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | SIGMAR1 605/4885HTR2C 1567/4885HTR2A 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.